x

AbbVie board OKs $1.5B for share buybacks

Print Page Updated: 03:45:03 PM, Fri 15 February 2013
NORTH CHICAGO, Ill. (AP) — Drugmaker AbbVie Inc., spun off from Abbott Laboratories in January, approved $1.5 billion for buying back its own shares.

The company expects the stock purchases to be completed over several years. Buybacks can make shareholders' existing holdings more valuable and boost earnings per share.

AbbVie, based in North Chicago, Ill., sells branded prescription drugs, including the blockbuster anti-inflammatory drug Humira, which is used to treat rheumatoid arthritis, psoriasis and Crohn's Disease.

Abbott, meanwhile, will continue marketing the company's remaining products: Nutritional formula, generic drugs and medical devices.

Company shares rose 98 cents, or 2.7 percent, to $37.55 in premarket trading.

Tags: ap, blockbuster, abbott laboratories, cents, shareholders, earnings, percent, stock, business, stock market, ill., premarket trading, pharmacology, medical devices, crohn, marketing the company s remaining products nutritional formula generic, north chicago, anti-inflammatory drug humira, branded prescription drugs, drugmaker abbvie inc., rheumatoid arthritis, abbvie board, stock purchases, share buybacks, company shares, psoriasis, adalimumab, infliximab, ankylosing spondylitis

Close
Loading
Close
Contact Us
Send Feedback X